Therapy of Experimental Babesiosis

Rowin, Kenneth S.; Tanowitz, Herbert B.; Wittner, Murray

doi:10.7326/0003-4819-97-4-556

Cited by 51 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient was then treated with quinine and clindamycin, which successfully eradicated the organisms. Subsequent studies in animals have supported the usefulness of this combination of antimicrobial agents (186). Comparisons between the duration of B. microti DNA (parasitemia) in babesiosis patients who were treated with quinine and clindamycin and babesiosis patients who were untreated showed that treatment reduces the duration of parasitemia (104).…”

Section: Treatmentmentioning

confidence: 95%

Babesiosis

Homer¹,

Aguilar-Delfín²,

Telford³

et al. 2000

Clinical Microbiology Reviews

522

402

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 95%

Babesiosis

Homer¹,

Aguilar-Delfín²,

Telford³

et al. 2000

Clinical Microbiology Reviews

522

402

View full text Add to dashboard Cite

“…In the early 1980s many traditional antiparasitic agents were evaluated for their therapeutic efficacies against babesiosis; however, only the combination of quinine and clindamycin was found to be adequately effective (18,105,138). In patients with life-threatening Babesia infections and high levels of parasitemia, red blood cell exchange transfusions may also be necessary (34,62).…”

Section: Review Of Clinical Trialsmentioning

confidence: 99%

Antiparasitic Agent Atovaquone

Baggish

Hill

2002

Antimicrob Agents Chemother

214

147

View full text Add to dashboard Cite

“…Therefore, for effective treatment of B. gibsoni, an alternative chemotherapeutic agent having few side effects is urgently needed. Clindamycin has been successfully used for the treatment of B. microti infection in hamsters and humans, and for the treatment B. canis infection in dogs [5,9,14,18]. Our previous studies indicated that clindamycin was successful for the treatment of B. rodhaini infection in mice, and might induce resistance to challenge infection in cured mice [21].…”

mentioning

confidence: 99%

Lymphocyte Subsets and Specific IgG Antibody Levels in Clindamycin-Treated and Untreated Dogs Experimentally Infected with Babesia gibsoni

Wulansari

Wijaya

Ano

et al. 2003

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. This study was carried out to clarify the role of lymphocyte subpopulations and Babesia-specific antibody on the treatment of clindamycin in dogs infected with B. gibsoni. Ten beagle dogs were divided into two groups: an untreated group (5 dogs) and a clindamycin-treated group (5 dogs), which was administered clindamycin at 25 mg/ kg body weight, per os, q 12 hr from 7 days to 21 d ays post-infection (PI). On the acute stage of infection, clindamycin treatment resolved anaemia and other clinical findings. There were no significant differences between treated and untreated dogs either in parasitemia levels or Babesial IgG antibody levels. However, morphological changes that indicated degeneration in the majority of parasites were observed. The numbers of CD4 + showed a significant increase in treated dogs, especially after treatment. On the chronic stage, CD4 + cells maintained high level both of the treated and untreated dogs. Although parasitemia maintained low level, their relapses were occurred on the 49th day PI in treated dogs and on the 42nd and 63rd PI in untreated dogs. A rapid humoral antibody response was observed in treated dogs, however, lower humoral anti body responses in untreated dogs after relapses. The antibody levels of treated dogs were significantly higher than those of untreated dogs. These results suggested that clindamycin might not eliminate rapidly parasites from peripheral blood, but damage parasites, whic h might stimulate efficiently humoral and cellular immunity against Babesia infection, and result in an improvement of clinical conditions.

show abstract

Therapy of Experimental Babesiosis

Cited by 51 publications

References 15 publications

Babesiosis

Babesiosis

Antiparasitic Agent Atovaquone

Lymphocyte Subsets and Specific IgG Antibody Levels in Clindamycin-Treated and Untreated Dogs Experimentally Infected with Babesia gibsoni

Contact Info

Product

Resources

About